MeCP2 controls hippocampal brain-derived neurotrophic factor expression via homeostatic interactions with microRNA-132 in rats with depression

Molecular Medicine Reports

Volumn 12, Issue 4, 2015, Pages 5399-5406

  Su, Meilei ^a   Hong, Jun ^a   Zhao, Yongzhi ^a   Liu, Shuai ^a   Xue, Xiang ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Brain derived neurotrophic factor; Homeostatic interaction; Major depressive disorder; Methyl CpG binding protein 2; microRNA

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; MESSENGER RNA; METHYL CPG BINDING PROTEIN 2; MICRORNA 132; MICRORNA; MIRN132 MICRORNA, RAT;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CHRONIC STRESS; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEMETHYLATION; DEPRESSION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED SWIM TEST; HIPPOCAMPUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEARNED HELPLESSNESS; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; RAT; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BLOOD; CASE CONTROL STUDY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HOMEOSTASIS; MAJOR DEPRESSION; METABOLISM; PHYSIOLOGICAL STRESS; RNA INTERFERENCE;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; CORTICOSTERONE; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HIPPOCAMPUS; HOMEOSTASIS; HUMANS; MALE; METHYL-CPG-BINDING PROTEIN 2; MICRORNAS; RATS; RNA INTERFERENCE; STRESS, PHYSIOLOGICAL;

EID: 84940546978     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4104     Document Type: Article

References (37)

1. Dwivedi Y: Emerging role of microRNAs in major depressive disorder: Diagnosis and therapeutic implications. Dialogues Clin Neurosci 16: 43-61, 2014.
2. Mouillet-Richard S, Baudry A, Launay JM and Kellermann O: MicroRNAs and depression. Neurobiol Dis 46: 272-278, 2012.
3. Sala M, Perez J, Soloff P, Ucelli di Nemi S, Caverzasi E, Soares JC and Brambilla P: Stress and hippocampal abnormalities in psychiatric disorders. Eur Neuropsychopharmacol 14: 393-405, 2004.
4. Li M, Fu Q, Li Y, Li S, Xue J and Ma S: Emodin opposes chronic unpredictable mild stress induced depressive-like behavior in mice by upregulating the levels of hippocampal glucocorticoid receptor and brain-derived neurotrophic factor. Fitoterapia 98: 1-10, 2014.
5. Maripuu M, Wikgren M, Karling P, Adolfsson R and Norrback KF: Relative hypo-and hypercortisolism are both associated with depression and lower quality of life in bipolar disorder: A cross-sectional study. PLoS One 9: e98682, 2014.
6. Réus GZ, Abelaira HM, Stringari RB, Fries GR, Kapczinski F and Quevedo J: Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in the prefrontal cortex induced by chronic mild stress in rats. Metab Brain Dis 27: 175-182, 2012.
7. Li YJ, Xu M, Gao ZH, Wang YQ, Yue Z, Zhang YX, Li XX, Zhang C, Xie SY and Wang PY: Alterations of serum levels of BDNF-related miRNAs in patients with depression. PLoS One 8: e63648, 2013.
8. Bai M, Zhu X, Zhang Y, Zhang S, Zhang L, Xue L, Yi J, Yao S and Zhang X: Abnormal hippocampal BDNF and miR-16 expression is associated with depression-like behaviors induced by stress during early life. PLoS One 7: e46921, 2012.
9. Bahi A, Chandrasekar V and Dreyer JL: Selective lentiviral-mediated suppression of microRNA124a in the hippocampus evokes antidepressants-like effects in rats. Psychoneuroendocrinology 46: 78-87, 2014.
10. O'Connor RM, Grenham S, Dinan TG and Cryan JF: microRNAs as novel antidepressant targets: Converging effects of ketamine and electroconvulsive shock therapy in the rat hippocampus. Int J Neuropsychopharmacol 16: 1885-1892, 2013.
11. Dell'Osso B, D'Addario C, Carlotta Palazzo M, Benatti B, Camuri G, Galimberti D, Fenoglio C, Scarpini E, Di Francesco A, Maccarrone M and Altamura AC: Epigenetic modulation of BDNF gene: Differences in DNA methylation between unipolar and bipolar patients. J Affect Disord 166: 330-333, 2014.
12. Zucchi FC, Yao Y, Ward ID, Ilnytskyy Y, Olson DM, Benzies K, Kovalchuk I, Kovalchuk O and Metz GA: Maternal stress induces epigenetic signatures of psychiatric and neurological diseases in the offspring. PLoS One 8: e56967, 2013.
13. Murgatroyd C, Wu Y, Bockmühl Y and Spengler D: Genes learn from stress: How infantile trauma programs us for depression. Epigenetics 5: 194-199, 2010.
14. Forlani G, Giarda E, Ala U, Di Cunto F, Salani M, Tupler R, Kilstrup-Nielsen C and Landsberger N: The MeCP2/Y Y1 interaction regulates ANT1 expression at 4q35: Novel hints for Rett syndrome pathogenesis. Hum Mol Genet 19: 3114-3123, 2010.
15. Hutchinson AN, Deng JV, Cohen S and West AE: Phosphorylation of MeCP2 at Ser421 contributes to chronic antidepressant action. J Neurosci 32: 14355-14363, 2012.
16. Murgatroyd C, Patchev AV, Wu Y, Micale V, Bockmühl Y, Fischer D, Holsboer F, Wotjak CT, Almeida OF and Spengler D: Dynamic DNA methylation programs persistent adverse effects of early-life stress. Nat Neurosci 12: 1559-1566, 2009.
17. Wada R, Akiyama Y, Hashimoto Y, Fukamachi H and Yuasa Y: miR-212 is downregulated and suppresses methyl-CpG-binding protein MeCP2 in human gastric cancer. Int J Cancer 127: 1106-1114, 2010.
18. Klein ME, Lioy DT, Ma L, Impey S, Mandel G and Goodman RH: Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat Neurosci 10: 1513-1514, 2007.
19. Im HI, Hollander JA, Bali P and Kenny PJ: MeCP2 controls BDNF expression and cocaine intake through homeostatic interactions with microRNA-212. Nat Neurosci 13: 1120-1127, 2010.
20. Luo YW, Xu Y, Cao WY, Zhong XL, Duan J, Wang XQ, Hu ZL, Li F, Zhang JY, Zhou M, Dai RP and Li CQ: Insulin-like growth factor 2 mitigates depressive behavior in a rat model of chronic stress. Neuropharmacology 89: 318-324, 2015.
21. Munno D, Sterpone S, Fania S, Cappellin F, Mengozzi G, Saroldi M, Bechon E and Zullo G: Plasma brain derived neurotrophic factor levels and neuropsychological aspects of depressed patients treated with paroxetine. Panminerva Med 55: 377-384, 2013.
22. Yu H, Wang DD, Wang Y, Liu T, Lee FS and Chen ZY: Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants. J Neurosci 32: 4092-4101, 2012.
23. Carballedo A, Amico F, Ugwu I, Fagan AJ, Fahey C, Morris D, Meaney JF, Leemans A and Frodl T: Reduced fractional anisotropy in the uncinate fasciculus in patients with major depression carrying the met-allele of the Val66Met brain-derived neurotrophic factor genotype. Am J Med Genet B Neuropsychiatr Genet 159B: 537-548, 2012.
24. Valvassori SS, Budni J, Varela RB and Quevedo J: Contributions of animal models to the study of mood disorders. Rev Bras Psiquiatr 35 (Suppl 2): S121-S131, 2013.
25. Xu X, Kozikowski AP and Pozzo-Miller L: A selective histone deacetylase-6 inhibitor improves BDNF traffcking in hippo-campal neurons from Mecp2 knockout mice: Implications for Rett syndrome. Front Cell Neurosci 8: 68, 2014.
26. Khoshnan A and Patterson PH: Elevated IKKα accelerates the differentiation of human neuronal progenitor cells and induces MeCP2-dependent BDNF expression. PLoS One 7: e41794, 2012.
27. Cortés-Mendoza J, Díaz de León-Guerrero S, Pedraza-Alva G and Pérez-Martínez L: Shaping synaptic plasticity: the role of activity-mediated epigenetic regulation on gene transcription. Int J Dev Neurosci 31: 359-369, 2013.
28. Lv J, Xin Y, Zhou W and Qiu Z. The epigenetic switches for neural development and psychiatric disorders. J Genet Genomics 40: 339-346, 2013.
29. Li H, Zhong X, Chau KF, Williams EC and Chang Q: Loss of activity-induced phosphorylation of MeCP2 enhances synapto-genesis, LTP and spatial memory. Nat Neurosci 14: 1001-1008, 2011.
30. Li W, Calfa G, Larimore J and Pozzo-Miller L: Activity-dependent BDNF release and TRPC signaling is impaired in hippocampal neurons of Mecp2 mutant mice. Proc Natl Acad Sci USA 109: 17087-17092, 2012.
31. Chang Q, Khare G, Dani V, Nelson S and Jaenisch R: The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 49: 341-348, 2006.
32. Zhou Z, Hong EJ, Cohen S, Zhao WN, Ho HY, Schmidt L, Chen WG, Lin Y, Savner E, Griffth EC, et al: Brain-specifc phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 52: 255-269, 2006.
33. Oved K, Morag A, Pasmanik-Chor M, Oron-Karni V, Shomron N, Rehavi M, Stingl JC and Gurwitz D: Genome-wide miRNA expression profling of human lymphoblastoid cell lines identifes tentative SSRI antidepressant response biomarkers. Pharmacogenomics 13: 1129-1139, 2012.
34. Scott HL, Tamagnini F, Narduzzo KE, Howarth JL, Lee YB, Wong LF, Brown MW, Warburton EC, Bashir ZI and Uney JB: MicroRNA-132 regulates recognition memory and synaptic plasticity in the perirhinal cortex. Eur J Neurosci 36: 2941-2948, 2012.
35. Shaltiel G, Hanan M, Wolf Y, Barbash S, Kovalev E, Shoham S and Soreq H: Hippocampal microRNA-132 mediates stress-inducible cognitive defcits through its acetylcholinesterase target. Brain Struct Funct 218: 59-72, 2013.
36. Abuhatzira L, Makedonski K, Kaufman Y, Razin A and Shemer R: MeCP2 defciency in the brain decreases BDNF levels by REST/CoREST-mediated repression and increases TRKB production. Epigenetics 2: 214-222, 2007.
37. Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J and Zoghbi H Y: MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320: 1224-1229, 2008.